Onkologie. 2021:15(2):77-85 | DOI: 10.36290/xon.2021.015

Treatment of relapsed and refractory multiple myeloma

Denisa Nováková, Jakub Radocha
IV. interní hematologická klinika, LF UK a FN Hradec Králové

Multiple myeloma is the second most common hematological malignancy in adults, which has been associated with an unfavorable prognosis and short survival of patients for decades.The development of new drugs, such as proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies, has significantly improved the survival and quality of life of a large portion of these patients. Despite advances in treatment, the disease remains difficult to cure and tends to recur over a variable time horizon. The treatment of relapsed or refractory disease is based on combinations of the above-mentioned groups of drugs. Their effectiveness, including safety profile, has been documented in a number of clinical studies. This article reviews the therapeutic options for patients with relapsed and refractory multiple myeloma.

Keywords: multiple myeloma, relapse, refractory, progression, novel therapy.

Published: April 29, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nováková D, Radocha J. Treatment of relapsed and refractory multiple myeloma. Onkologie. 2021;15(2):77-85. doi: 10.36290/xon.2021.015.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma. The Lancet Oncology 2014; 15(12): e538-548. Go to original source... Go to PubMed...
    2. Rajkumar S. Vincent. Treatment of Multiple Myeloma. Nature Reviews Clinical Oncology 2011; 8(8): 479-491. Go to original source... Go to PubMed...
    3. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, et al. Continued Improvement in Survival in Multiple Myeloma: Changes in Early Mortality and Outcomes in Older Patients. Leukemia 2014; 28(5): 1122-1128. Go to original source... Go to PubMed...
    4. Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, Gertz MA, et al. Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. Mayo Clin Proc. 2017; 92(4): 578-598. doi: 10.1016/j.mayocp.2017.01.003. Epub 2017 Mar 11. PMID: 28291589; PMCID: PMC5554888. Go to original source... Go to PubMed...
    5. Diagnostika a léčba mnohočetného myelomu. Transfuze a hematologie dnes, 2018; 24(Suppl. 1): 7-23.
    6. Dimopoulos MA, Meletios A, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, et al. Carfilzomib and Dexamethasone versus Bortezomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (ENDEAVOR): A Randomised, Phase 3, Open-Label, Multicentre Study. The Lancet Oncology 2016; 17(1): 27-38. Go to original source... Go to PubMed...
    7. Stewart A, Keith S, Rajkumar V, Meletios A. Dimopoulos, Masszi T, Špička I, Oriol A, Hájek R, et al. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. Research-article. http://dx.doi.org/10.1056/NEJMoa1411321. Massachusetts Medical Society, 7. leden 2015. Go to original source...
    8. Philippe M, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, Dimopoulos MA, Huang M, Zahlten-Kumeli A, Stewart AK. Once Weekly versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Interim Analysis Results of a Randomised, Phase 3 Study. The Lancet Oncology 2018; 19(7): 953-964. Go to original source... Go to PubMed...
    9. Philippe M, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. Research-article. https://doi.org/10.1056/NEJMoa1516282. Massachusetts Medical Society, 27. duben 2016. World. Go to original source...
    10. Paul R, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, Williams SF, et al. Safety and Efficacy of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma. Blood 2009; 114(4): 772-778. Go to original source... Go to PubMed...
    11. Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, et al. Long-Term Follow-up on Overall Survival from the MM-009 and MM-010 Phase III Trials of Lenalidomide plus Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. Leukemia 2009; 23(11): 2147-2152. Go to original source... Go to PubMed...
    12. Richardson Paul G, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, Alsina M, et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood 2014; 123(10): 1461-1469. Go to original source... Go to PubMed...
    13. Tomer M, Coleman M, Niesvizky R. Preclinical and Clinical Results with Pomalidomide in the Treatment of Relapsed/Refractory Multiple Myeloma. Leukemia Research 2014; 38(5): 517-524. Go to original source... Go to PubMed...
    14. Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, et al. Pomalidomide plus Low-Dose Dexamethasone versus High-Dose Dexamethasone Alone for Patients with Relapsed and Refractory Multiple Myeloma (MM-003): A Randomised, Open-Label, Phase 3 Trial. Lancet Oncol. 2013; 14(11): 1055-1066. Go to original source... Go to PubMed...
    15. Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, et al. Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with Lenalidomide (OPTIMISMM): A Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology 2019; 20(6): 781-794. Go to original source... Go to PubMed...
    16. Michel A, Richardson PG, Rajkumar VS, San-Miguel J, Beksac M, Spicka I, Leleu X, et al. Isatuximab plus Pomalidomide and Low-Dose Dexamethasone versus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma (ICARIA-MM): A Randomised, Multicentre, Open-Label, Phase 3 Study. The Lancet 2019; 394(10214): 2096-2107. Go to original source... Go to PubMed...
    17. Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, et al. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. New England Journal of Medicine 2018; 379(19): 1811-1822. Go to original source... Go to PubMed...
    18. Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, Snowden JA, et al. The Effect of Salvage Autologous Stem-Cell Transplantation on Overall Survival in Patients with Relapsed Multiple Myeloma (Final Results from BSBMT/UKMF Myeloma X Relapse [Intensive]): A Randomised, Open-Label, Phase 3 Trial. The Lancet Haematology 2016; 3(7): e340-351. Go to original source... Go to PubMed...
    19. Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC. Management of Relapsed and Refractory Multiple Myeloma: Novel Agents, Antibodies, Immunotherapies and Beyond. Leukemia 2018; 32(2): 252-262. Go to original source... Go to PubMed...
    20. Hyun LJ, Kim SH. Treatment of Relapsed and Refractory Multiple Myeloma. Blood Research 2020; 55(0): S43-53. Go to original source... Go to PubMed...
    21. Massimo G, Vigna E, Recchia AG, Morabito L, Mendicino F, Giagnuolo G, Morabito F. Bendamustine in Multiple Myeloma. European Journal of Haematology 2015; 95(5): 377-388. Go to original source... Go to PubMed...
    22. Dharshan S, Green MM, Kang Y, Long GD, Rizzieri DA, Li Z, Garrett AH, McIntyre JL, Chao NJ, Gasparetto C. Bendamustine, Pomalidomide, and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma. Blood Cancer Journal 2018; 8(8): 1-4. Go to original source... Go to PubMed...
    23. Binod D, D'Souza A, Hamadani M, Arce-Lara C, Schroeder K, Chhabra S, Shah NN, et al. Phase I/II Trial of Bendamustine, Ixazomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma. Blood Cancer Journal 2019; 9(8): 1-7. Go to original source... Go to PubMed...
    24. Chim C, Kumar S, Orlowski R, Cook G, Richardson P, Gertz M, Giralt S, Mateos M, Leleu X, Anderson K. Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond. Leukemia 2017; 32. Go to original source... Go to PubMed...
    25. Usmani SZ, Nahi H, Plesner T, Weiss BM, Bahlis NJ, Belch A, Voorhees PM, et al. Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma: Final Results from the Phase 2 GEN501 and SIRIUS Trials. The Lancet Haematology 2020; 7(6): e447-455. Go to original source... Go to PubMed...
    26. Meletios DA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. Research-article. https://doi.org/10.1056/NEJMoa1607751. Massachusetts Medical Society, 5. říjen 2016. World. Go to original source...
    27. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. Research-article. https://doi.org/10.1056/NEJMoa1606038. Massachusetts Medical Society, 24. srpen 2016. Go to original source...
    28. Sagar L, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine 2015; 373(7): 621-631. Go to original source... Go to PubMed...
    29. Joshua R, Madduri D, Richard S, Chari A. Selinexor in relapsed/refractory multiple myeloma. Therapeutic Advances in Hematology 11 (9. červen 2020). Go to original source... Go to PubMed...
    30. Ajai CH, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Carol A. Huff, Philippe Moreau, et al. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. New England Journal of Medicine 2019; 381(8).
    31. Shaji K, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, Benboubker L, et al. Efficacy of Venetoclax as Targeted Therapy for Relapsed/Refractory t (11;14) Multiple Myeloma. Blood 2017; 130(22): 2401-2409. Go to original source... Go to PubMed...
    32. Philippe M, Harrison S, Cavo M, De La Rubia J, Popat R, Gasparetto C, Vania TM. Hungria, et al. Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood 2019; 134(Suppl. 1): 888-1888. Go to original source...
    33. Bo Y, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. Journal of Hematology & Oncology 2020; 13. Go to original source... Go to PubMed...
    34. Lonial, Sagar, Hans C Lee, Ashraf Badros, Suzanne Trudel, Ajay K Nooka, Ajai Chari, Al-Ola Abdallah, et al. "Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma (DREAMM-2): A Two-Arm, Randomised, Open-Label, Phase 2 Study". The Lancet Oncology 2020; 21(2): 207-221. Go to original source... Go to PubMed...
    35. Deepu M, Berdeja JG, Usmani SZ, Jakubowiak A, Agha M, Adam D, Cohen A, Stewart K, et al. CARTITUDE-1: Phase 1 b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma. Blood 2020; 136(Suppl. 1): 22-25.
    36. Munshi, Nikhil C, Jr Anderson Larry D, Shah N, Jagannath S, Berdeja JG, Lonial S, Raje NS, et al. Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results. Journal of Clinical Oncology 2020; 38(Suppl. 15): 8503-8503. Go to original source...
    37. Herrmann, Banchs J, Hajek R, et al. Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. Blood Advances 2018; 2(13): 1633-1644. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.